Addex TherapeuticsADXN
13F holders, Q1 2026 (March 31)4holders −1
0new positions
1sold out
$6.28avg. 13F price*
At the end of Q1 2026, 4 institutions reported holding Addex Therapeutics Ltd. (ADXN) in their 13F filings, down 1 from Q4 2025. 0 opened new positions and 1 sold out. The largest holders were Morgan Stanley ($2K), GAMMA Investing LLC ($509) and Rhumbline Advisers ($450).
- Company
- Addex Therapeutics Ltd.
- CUSIP
- 00654J206
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 1 | $1K |
All 13F filers, Q4 2025 → Q1 2026: 1 shares bought and 156 shares sold, net −155 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 4 holders
| Morgan Stanley | 0.00% | Add +0.3% | 301 | $2K |
| GAMMA Investing LLC | 0.00% | No change | 81 | $509 |
| Rhumbline Advisers | 0.00% | No change | 72 | $450 |
| SBI Securities Co., Ltd. | 0.00% | No change | 1 | $6 |
"% of holder's portfolio" is ADXN's weight in each manager's 13F, not the share of Addex Therapeutics Ltd. the manager owns.